Back to news

Post Scheme of Arrangement, India Glycols reports its first financial results for Q2 FY27, Revenue of Rs. 358.18 Crore and EBITDA of Rs. 39.34 Crore

PR Newswire•17/11/2026•08:12 ET
0

Key Highlights

  • ➤Q2 FY27 revenue Rs. 358.18 crore following demerger
  • ➤Q2 FY27 EBITDA Rs. 39.34 crore
  • ➤Q2 FY27 PAT Rs. 11.24 crore
  • ➤Demerger separated Spirits, Biofuel and Biopharma undertakings into two listed entities
  • ➤H1 FY27 revenue Rs. 712.82 crore and EBITDA Rs. 79.55 crore

Expert Statements

Rupark Sarswat, Chief Executive Officer, India Glycols Limited

“The implementation of the demerger marks an important step in the evolution of India Glycols, enabling a sharper focus on our core business of bio-based specialities and performance chemicals. We remain focused on strengthening our capabilities, enhancing operational efficiencies and building on our expertise in the bio-based chemicals space. Going forward, our efforts will be directed towards expanding our business opportunities and creating sustainable long-term value for our stakeholders.”

Post Scheme of Arrangement, India Glycols reports its first financial results for Q2 FY27, Revenue of Rs. 358.18 Crore and EBITDA of Rs. 39.34 Crore PR Newswire

NOIDA, India, Nov. 17, 2026 /PRNewswire/ -- India Glycols Limited (NSE: INDIAGLYCO) (BSE: 500201) has announced its unaudited standalone financial results for the second quarter (Q2 FY27) and half year (H1 FY27) ended September 30, 2026. These results cover only the Company's continuing operations which retains Biobased Specialty Materials; Sustainable & Performance Chemicals, Gases. Its Spirits & Biofuel Undertaking and its Biopharma Undertaking have been demerged into IGL Spirits Limited and Ennature Bio Pharma Limited, and both are now separately listed. India Glycols' Revenue and EBITDA for the period are as follows:

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in